About C4X Discovery C4X Discovery (C4XD) aims to create the world s most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company s business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study. C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology).
4Bio Capital: Appointment of Professor Akiko Iwasaki to Scientific Advisory Board
Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University
Principal investigator at the Howard Hughes Medical Institute
Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19
18 December 2020
LONDON & BOSTON - 4BIO Capital ( 4BIO or the Group ), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB).
Professor Iwasaki has made significant contributions towards understanding innate and adaptive immunity. Throughout her research career she has made major breakthroughs including the demonstration of tissue-specific properties of dendritic cells, how DNA vaccines elicit an immune response, and being the first group to create a mouse model of vaginal Zika infection. She has received a numbe
Appointment of Professor Akiko Iwasaki to Scientific Advisory Board
December 18, 2020 07:00 ET | Source: 4Bio Capital 4Bio Capital
Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University
Principal investigator at the Howard Hughes Medical Institute
Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19
18 December 2020
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB).
Professor Iwasaki has made significant contributions towards understanding innate and adaptive immunity. Throughout her research career she has made major breakthroughs including the demonstration of tissue-specific properties of dendritic cells, how DNA vaccines elicit an immune response, and bei
Share:
TM device and disposable test cassette
-
Q-POC™ is a point of care molecular diagnostic system which delivers results in approximately 30 minutes; first application in COVID-19
NEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over £11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC™ and disposable test cassette.
QuantuMDx accelerated development, scale-up and manufacture of Q-POC™ - its rapid point-of-care testing system - earlier this year in response to the COVID-19 pandemic.
Q-POC™ is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes. The Q-POC™ system comprises a sample collection kit, single-use test cassette a
Share:
GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.
Berlin, Germany, December 17, 2020 - Glycotope GmbH, an oncology/immuno-oncology platform company built on world-leading glycobiology expertise, today announces that is has signed an agreement to license a humanized, tumor-specific antibody (GlycoBody) targeting an aberrantly glycosylated tumor associated form of MUC1 (TA-MUC1) to ONK Therapeutics Ltd. (ONK), an innovative natural killer (NK) cell therapy company.
The GlycoBody will be integrated into ONKs pre-clinical program ONKT103, for solid tumors. ONK s unique platform approach combines the expression of a chimeric antigen receptor (CAR) and a high affinity, membrane-bound TNF related apoptosis inducing ligand variant (TRAILv).